ReviewArthritis research & therapy2010
The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review.
Review in Arthritis research & therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis.RMD open · 2024Pooled it
- Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis.Rheumatology (Oxford, England) · 2019Pooled it
- Trial
- An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.Arthritis research & therapy · 2019Trial
- Association of serum adalimumab levels and immunogenicity with clinical response in non-infectious uveitis: a real-world cohort study.Frontiers in immunology · 2026Observational
- Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics.Life science alliance · 2024Article
- No Correlation between Anti-drug Antibodies and Therapeutic Response in Tunisian Patients with Chronic Inflammatory Diseases Treated by TNF Blockers.Current rheumatology reviews · 2024Article
- B cells in autoimmune hepatitis: bystanders or central players?Seminars in immunopathology · 2022Review
- Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis.Rheumatology international · 2022Article
- Anti-drug antibodies in the current management of cancer.Cancer chemotherapy and pharmacology · 2022Review
- Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology.Journal for immunotherapy of cancer · 2022Review
- Factors associated with drug survival on first biologic therapy in patients with rheumatoid arthritis: a population-based cohort study.Rheumatology international · 2021Article
- Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease.Journal of clinical pharmacology · 2021Article
- Refractory Pediatric Psoriasis and Atopic Dermatitis: The Importance of Therapeutical Adherence and Biological Management.Biomedicines · 2021Review
- Anti-TNF therapy and immunogenicity in inflammatory bowel diseases: a translational approach.American journal of translational research · 2021Article
- Adalimumab Immunogenicity Is Negatively Correlated with Anti-Hinge Antibody Levels in Patients with Rheumatoid Arthritis.The Journal of pharmacology and experimental therapeutics · 2020Article
- Article
- Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications.Clinical pharmacokinetics · 2020Review
- Mécanisme d'action du méthotrexate dans le traitement de la polyarthrite rhumatoïde.Revue du rhumatisme (Ed. francaise : 1993) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic monoclonal antibodies have revolutionized the treatment of various inflammatory diseases. Immunogenicity against these antibodies has been shown to be clinically important: it is associated with shorter response duration because of diminishing concentrations in the blood and with infusion reactions. Concomitant immunomodulators in the form of methotrexate or azathioprine reduced the immunogenicity of therapeutic antibodies in rheumatoid arthritis, Crohn disease, and juvenile idiopathic arthritis. The occurrence of adverse events does not increase when immunomodulators are added to therapeutic antibodies. The mechanism whereby methotrexate and azathioprine influence immunogenicity remains unclear. Evidence-based consensus on prescribing concomitant immunomodulators is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.